Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.74 USD | +1.76% | +3.39% | -13.14% |
May. 10 | Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating | MT |
May. 08 | Transcript : Mirum Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.14% | 1.19B | |
+39.01% | 54.04B | |
+44.93% | 41.96B | |
-1.33% | 41.92B | |
-7.20% | 28.35B | |
+12.51% | 26.35B | |
-21.74% | 19B | |
+7.04% | 13B | |
+29.20% | 12.28B | |
+26.42% | 12.19B |
- Stock Market
- Equities
- MIRM Stock
- News Mirum Pharmaceuticals, Inc.
- Raymond James Trims Price Target on Mirum Pharmaceuticals to $81 From $83, Maintains Strong Buy Rating